banter and General Discussion, page-8332

MPC-06-ID is different to Remestemcel-L, therefore the FDA CRL and the reasons stated within should not cause delays with CLBP directly. Remestemcel-L including its potency assays came with a "tarnished" track record from its Osiris Prochymal days already, which the FDA has referenced on various occasions during the ODAC meeting (and can still be found on the ODAC meeting papers). Your MPC platform product in CLBP does not face these challenges.

Therefore, I think it would be wise to progress both platforms in parallel - if the funds allow. And based on the 2023 Annual Report it appears that this is what MSB is going to do.

However, there would have been an indirect impact due to funds raised and allocated to progress CLBP last year would have had to be re-allocated given that the anticipated marketing approval delayed the expected revenue stream further and required more work to be done (and paid for) to re-apply.